Effect of selenium and zinc biofortification on the biochemical parameters of Pleurotus spp. under submerged and solid-state fermentation.

BACKGROUND: Pleurotus has a remarkable nutritional and nutraceutical profile due to mineral mobilization and accumulation abilities from the substrate. The present study aimed to observe the effect of single and dual supplementations Se and Zn on biochemical parameters of P. florida, P. sajor caju and P. djamor. Also, the bioaccumulation of the trace elements in fortified mushrooms was estimated. METHODS: Biomass production and radial growth rate were observed on Se and Zn supplemented broth and agar based medium. Furthermore, the influence of Se and Zn supplementation was recorded on the fruit body yield. The colorimetric assays were employed to estimate total soluble protein, total phenol and total flavonoid contents. The antioxidant activity was assayed as DPPH radical scavenging test. While, ICP-AES was performed to estimate the variation in the Zn and Se content of the fruit bodies. RESULTS: The Se supplementation at low rate resulted in improvement in the radial growth rate and biomass production for P. sajor caju. For solid-state fermentation, a better yield was obtained with inorganic salt supplementation in comparison to organically enriched Se straw. The maximum total soluble protein content and total flavonoid content were observed in fruit bodies of P. sajor caju at 4 mg L -1 of Se and Se-Zn respectively. Pleurotus djamor exhibited the highest total phenolic content on Zn supplementation (10 mg L-1). Improved antioxidant potential was recorded with dual supplementations. Salt supplementations caused shrinkage, distortion of the fungal hyphae, and decreased basidiospores with significant amelioration in elemental composition in fortified mushrooms. CONCLUSION: The inorganic salt supplementation increased the biochemical potential of Pleurotus spp. in comparison to organically enriched substrate which could further be used for the development of dietary supplements.

Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.

Invasive fungal infections in humans are common in people with compromised immune systems and are difficult to treat, resulting in high mortality. Amphotericin B (AmB) is one of the main antifungal drugs available to treat these infections. AmB binds with plasma membrane ergosterol, causing leakage of cellular ions and promoting cell death. The increasing use of available antifungal drugs to combat pathogenic fungal infections has led to the development of drug resistance. AmB resistance is not very common and is usually caused by changes in the amount or type of ergosterol or changes in the cell wall. Intrinsic AmB resistance occurs in the absence of AmB exposure, whereas acquired AmB resistance can develop during treatment. However, clinical resistance arises due to treatment failure with AmB and depends on multiple factors such as the pharmacokinetics of AmB, infectious fungal species, and host immune status. Candida albicans is a common opportunistic pathogen that can cause superficial infections of the skin and mucosal surfaces, thrush, to life-threatening systemic or invasive infections. In addition, immunocompromised individuals are more susceptible to systemic infections caused by Candida, Aspergillus, and Cryptococcus. Several antifungal drugs with different modes of action are used to treat systemic to invasive fungal infections and are approved for clinical use in the treatment of fungal diseases. However, C. albicans can develop a variety of defenses against antifungal medications. In fungi, plasma membrane sphingolipid molecules could interact with ergosterol, which can lead to the alteration of drug susceptibilities such as AmB. In this review, we mainly summarize the role of sphingolipid molecules and their regulators in AmB resistance.

Cordycepin as a Metabolite with Pharmacological Potential: A Review.

The pharmacological values of Cordyceps spp. are substantially associated with the existence of an extremely potent biometabolite: cordycepin. This component exhibits powerful therapeutic activity against cancer, diabetes, and hyperlipidemia and acts as a strong immunomodulator. Extensive pharmaceutical exploitation of Cordyceps spp. has depleted its natural existence. Therefore, there is a strong need for metabolic engineering-based approaches that could be employed for overproduction of the desired metabolite, which would sustain market demands. Replacement of the old conventional genome editing tools by the newly developed CRISPR technology is considered a suitable alternative for enhancing metabolite production. Another novel approach, POPCORN, optimizes carbon/nitrogen ratios to design synthetic media for Cordyceps production. In fact, the addition of FeSO4 and porcine liver extract and alterations in the dissolved oxygen enhanced cordycepin production in the submerged state. Ultraviolet mutagenesis is another approach for the augmentation of this pharmaceutically potent biometabolite. Therefore, the main objective of this review is to present the outlook on pharmaceutical properties of cordycepin along with the metabolic approaches for enhancing cordycepin production.